Clinical Trials Directory

Trials / Conditions / EGFR T790M

EGFR T790M

10 registered clinical trials studyying EGFR T790M — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingEvaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutati
NCT06573073
LifeOS Genomics Corporation—
UnknownLazertinib 160mg in EGFR T790M NSCLC
NCT05701384
Samsung Medical CenterPhase 2
UnknownLazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lun
NCT05377788
Samsung Medical Center—
Terminated(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
NCT04862780
Blueprint Medicines CorporationPhase 1
UnknownAlmonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer
NCT04592666
Fudan UniversityPhase 2
UnknownCorrelation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC
NCT05458726
Peking Union Medical CollegePhase 2
UnknownCombination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
NCT03532698
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University—
CompletedExploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
NCT03810066
University Hospital, EssenPhase 2
CompletedD-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
NCT03861156
InventisBio Co., LtdPhase 2
CompletedCombination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
NCT03543683
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityPhase 2